Antibody Development Segment has the Largest Share of Service in the Asia Pacific Custom Antibody Market during 2021-2028
According to a new market research study on “Asia Pacific Custom Antibody Market to 2028 - COVID-19 Impact and Regional Analysis and Forecast by Service, Type, Source, Research Area, and End-user,” is expected to reach US$ 174.8 million by 2028 from US$ 82.3 million in 2021. The market is estimated to grow at a CAGR of 11.4% from 2021 to 2028. The report provides trends prevailing in the Asia Pacific custom antibody market along with the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high demand in research, market consolidations strategies adopted by biotechnology companies, and production and development services offered by custom antibody providers are the key factors driving the market growth. However, the market is expected experiencing slow growth during the forecast period owing to the high cost of production.
Countries in the Asia Pacific are encountering challenges due to rising incidences of COVID-19. The COVID-19 pandemic has put a significant strain on the health systems of many countries around the world. Testing capacity in many Asia Pacific nations was limited and of low quality in the initial days of the pandemic, which led to a surge in the COVID-19 cases. However, many countries, such as South Korea, Japan, and Singapore, were efficiently contained the situation through robust tracking and testing. Also, India has the second-highest number of cases in the world after the US. Thus, COVID-19 has created an extraordinary emergency that is particularly affecting the supply chain. The supply chain disruptions, along with the enormous demand for effective diagnostics and therapeutics for the treatment of COVID 19, have put the healthcare research industry in a critical situation in the Asia Pacific region. However, many market players now realized the importance of antibody testing for COVID 19, which is expected to raise demand for custom antibodies during the forecast period.
The market for custom antibody market is segmented into service, type, source, research area, and End-user. Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, antibody fragmentation and labelling. In 2020, the antibody development segment held the largest share of the market, also the same segment is estimated to grow at a significant CAGR due to growing focus of researchers on high-quality custom antibodies for reproducibility during the forecast period.
Thermo Fisher Scientific Inc. Bio-Rad Laboratories Inc. Merck KGAA, Abcam, Genscript, Agilent Technologies, Inc. and Cell Signaling Technology, Inc. are among the leading companies in the Asia Pacific custom antibody market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2020, Thermo Fisher Scientific has entered into collaboration with WuXi Diagnostics and the Mayo Clinic to develop ELISA test for detection of IgM and IgG antibodies to the novel coronavirus.
Countries in the Asia Pacific are encountering challenges due to rising incidences of COVID-19. The COVID-19 pandemic has put a significant strain on the health systems of many countries around the world. Testing capacity in many Asia Pacific nations was limited and of low quality in the initial days of the pandemic, which led to a surge in the COVID-19 cases. However, many countries, such as South Korea, Japan, and Singapore, were efficiently contained the situation through robust tracking and testing. Also, India has the second-highest number of cases in the world after the US. Thus, COVID-19 has created an extraordinary emergency that is particularly affecting the supply chain. The supply chain disruptions, along with the enormous demand for effective diagnostics and therapeutics for the treatment of COVID 19, have put the healthcare research industry in a critical situation in the Asia Pacific region. However, many market players now realized the importance of antibody testing for COVID 19, which is expected to raise demand for custom antibodies during the forecast period.
The market for custom antibody market is segmented into service, type, source, research area, and End-user. Based on service, the custom antibody market is segmented into antibody development, antibody production and purification, antibody fragmentation and labelling. In 2020, the antibody development segment held the largest share of the market, also the same segment is estimated to grow at a significant CAGR due to growing focus of researchers on high-quality custom antibodies for reproducibility during the forecast period.
Thermo Fisher Scientific Inc. Bio-Rad Laboratories Inc. Merck KGAA, Abcam, Genscript, Agilent Technologies, Inc. and Cell Signaling Technology, Inc. are among the leading companies in the Asia Pacific custom antibody market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2020, Thermo Fisher Scientific has entered into collaboration with WuXi Diagnostics and the Mayo Clinic to develop ELISA test for detection of IgM and IgG antibodies to the novel coronavirus.
The report segments the Asia Pacific Custom Antibody market as follows:
By Service
- Antibody Development
- Antibody Production and Purification
- Antibody Fragmentation and Labelling
By Type
- Monoclonal Antibodies
- Polyclonal Antibodies
- Other Custom Antibodies
By Source
- Mice
- Rabbits
- Others
By Research Area
- Oncology
- Immunology
- Stem Cells
- Infectious Diseases
- Neurobiology
- Cardiovascular Diseases
- Others
By End-user
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Contract Research Organizations
By Country
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
Reasons to buy:
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Asia Pacific custom antibody market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific custom antibody market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the custom antibody market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution
Table of Contents
1. Introduction
3. Research Methodology
4. Asia Pacific Custom Antibody Market - Market Landscape
5. Asia Pacific Custom Antibody Market - Key Market Dynamics
6. Custom Antibody Market - Asia Pacific Analysis
7. Asia Pacific Custom Antibody Market Analysis and Forecasts To 2028 - By Service
8. Asia Pacific Custom Antibody Market Analysis and Forecasts To 2028 - By Type
9. Asia Pacific Custom Antibody Market Analysis and Forecasts To 2028 - By Source
10. Asia Pacific Custom Antibody Market Analysis and Forecasts to 2028 - By Research Area
11. Asia Pacific Custom Antibody Market Analysis and Forecasts to 2028 - By End User
12. Custom Antibody Market Revenue and Forecasts to 2028 - Geographical Analysis
13. Impact Of COVID-19 Pandemic on Asia Pacific Custom Antibody Market
14. Industry Landscape
15. COMPANY PROFILES
16. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories Inc.
- Merck KGAA
- Abcam
- Genscript
- Agilent Technologies, Inc.
- Cell Signaling Technology, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | July 2021 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 82.3 Million |
| Forecasted Market Value ( USD | $ 174.8 Million |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Asia Pacific |
